Preventive Effects of Transdermal Administration of 17β-Estradiol on Postmenopausal Bone Loss

Publisher Website
Google Scholar
Abstract
A 2-year prospective study was conducted on 44 early postmenopausal women to assess the effect of transdermal estradiol (TTS-E2) on vertebral bone mass. Twenty treated women and 24 untreated were studied. Treatment consisted of TTS-E2 (0.05 mg/day, 3 weeks a month) and an oral gestagen (10 days per month). At 24 months, bone mineral density, measured by dual photon absorptiometry (DPA), decreased significantly in untreated women (-4.3%) (P